Asset Details
Do you wish to reserve the book?
Herpes Simplex Virus (HSV)-Suppressive Therapy Decreases Plasma and Genital HIV-1 Levels in HSV-2/HIV-1 Coinfected Women: A Randomized, Placebo-Controlled, Cross-Over Trial
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Herpes Simplex Virus (HSV)-Suppressive Therapy Decreases Plasma and Genital HIV-1 Levels in HSV-2/HIV-1 Coinfected Women: A Randomized, Placebo-Controlled, Cross-Over Trial
Do you wish to request the book?
Herpes Simplex Virus (HSV)-Suppressive Therapy Decreases Plasma and Genital HIV-1 Levels in HSV-2/HIV-1 Coinfected Women: A Randomized, Placebo-Controlled, Cross-Over Trial
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Herpes Simplex Virus (HSV)-Suppressive Therapy Decreases Plasma and Genital HIV-1 Levels in HSV-2/HIV-1 Coinfected Women: A Randomized, Placebo-Controlled, Cross-Over Trial
2008
Overview
A randomized cross-over trial of herpes simplex virus type 2 (HSV-2)-suppressive therapy (valacyclovir, 500 mg twice daily, or placebo for 8 weeks, a 2-week washout period, then the alternative therapy for 8 weeks) was conducted among 20 Peruvian women coinfected with HSV-2 and human immunodeficiency virus type 1 (HIV-1) who were not on antiretroviral therapy. Plasma samples (obtained weekly) and endocervical swab specimens (obtained thrice weekly) were collected for HIV-1 RNA polymerase chain reaction. Plasma HIV-1 level was significantly lower during the valacyclovir arm, compared with the placebo arm (−0.26 log10 copies/mL, a 45% decrease [P<.001]), as was cervical HIV-1 level (−0.35 log10 copies/swab, a 55% decrease [P<.001]). Suppressive HSV-2 therapy has the potential to reduce HIV-1 infectiousness and slow HIV-1 disease progression. Trial registration. ClinicalTrials.gov identifier: NCT00465205.
Publisher
The University of Chicago Press,University of Chicago Press,Oxford University Press
Subject
Acyclovir - analogs & derivatives
/ Adult
/ Antiviral Agents - therapeutic use
/ Biological and medical sciences
/ Female
/ Fundamental and applied biological sciences. Psychology
/ Herpes Simplex - complications
/ Herpes Simplex - drug therapy
/ Herpesvirus 2, Human - isolation & purification
/ HIV 1
/ HIV Infections - complications
/ HIV-1 - isolation & purification
/ HIV/AIDS
/ Human immunodeficiency virus 1
/ Human immunodeficiency virus 2
/ Humans
/ Placebos
/ RNA
/ Valine - analogs & derivatives
/ Virology
